Evolution of HER2-low expression from primary to recurrent breast cancer.
Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Conte P, Guarneri V, Dieci MV.
Miglietta F, et al.
NPJ Breast Cancer. 2021 Oct 12;7(1):137. doi: 10.1038/s41523-021-00343-4.
NPJ Breast Cancer. 2021.
PMID: 34642348
Free PMC article.
HER2 was evaluated according to ASCO/CAP recommendations in place at the time of diagnosis. A cutoff of >10% cells staining for HER2-positivity was applied. HER2-negative cases were sub-classified as HER2-low (IHC = 1 + /2+ and ISH not amplified), or HER2-0 (IHC-0). 547 …
HER2 was evaluated according to ASCO/CAP recommendations in place at the time of diagnosis. A cutoff of >10% cells staining for HE …